Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.
about
The biological characterization of neuroendocrine tumors: the role of neuroendocrine markersPancreastatin predicts survival in neuroendocrine tumors.The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.Biochemical prognostic indicators for pancreatic neuroendocrine tumors and small bowel neuroendocrine tumorsThe association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional studyPrognostic significance of lymph node metastases in small intestinal neuroendocrine tumorsGuidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)Primary hepatic neuroendocrine tumors: comparing CT and MRI features with pathologyMelatonin Immunoreactivity in Malignant Small Intestinal Neuroendocrine TumoursBiochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine TumorsDifferential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases.Alpha-fetoprotein and human chorionic gonadotrophin-beta as prognostic markers in neuroendocrine tumour patients.High expression of substance P and its receptor neurokinin-1 receptor in colorectal cancer is associated with tumor progression and prognosis.Consensus on biomarkers for neuroendocrine tumour diseaseGuidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour groupIs visual radiological evaluation of liver tumour burden in patients with neuroendocrine tumours reproducible?AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoidsNeuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.The use of biomarkers in neuroendocrine tumours.Serum pancreastatin: the next predictive neuroendocrine tumor marker.Treatment, prognostic markers, and survival in thymic neuroendocrine tumors: A single center experience of 41 patients.Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms.Neurokinin A monitoring of response to interferon alpha in a patient with an advanced small bowel neuroendocrine tumour uncontrolled by somatostatin analogue therapy.Biochemical Testing in Neuroendocrine Tumors.Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor.Raised circulating Neurokinin A predicts prognosis in metastatic small bowel neuroendocrine tumours. Lowering Neurokinin A indicates improved prognosis.Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement
P2860
Q28275872-8E6FF0D1-BD7D-48B8-BC03-79C3780A75F8Q34016884-427CBDAF-DC2A-4CE1-AA38-54B7D9E53CA2Q34031906-04633A3B-5105-4369-B4AC-9A44AF38A5FEQ34573558-0B70982F-930B-4AA2-AF22-485E58F68BC4Q34998790-86C0C9CF-F369-42CF-8A4A-BA119F782E6FQ35486383-BE06D5A6-8561-4A72-AC46-F9FF769D973DQ35760798-173AF549-F269-40C4-A634-BE83D5F85F53Q35954314-D3A3ECE0-A55D-41BF-A330-8D74D2769694Q36162902-62AE3679-C320-4B98-B96E-90EC83CB73A5Q36330126-EA2538F9-912E-4FDE-949F-4C5F1012B9B5Q36665034-D5E0C100-90F6-4F81-B946-D4B6363F94F1Q36755251-02909D12-0DD1-4655-9113-3C160D0C435EQ37021243-D28FD68B-CFE3-431A-99AD-E18A2CB3D297Q37255681-DE66BE0B-561F-45E6-91B8-C49E706EB7D9Q37629658-9190E1A5-D6D3-49E1-B066-F9C573773797Q37635803-4CFC3DE0-5D60-4ED8-A184-1DD4C0F6C629Q38472683-2C841A40-B65D-439F-998C-52AA290FFDE7Q38483236-D96EEC6A-E11D-48E8-AE2A-E4B29D5C6656Q38609117-6C31A34E-6276-4FA5-9E20-3ABD3E552CC2Q44969569-57810BC9-5855-496C-80A2-9610787EEA73Q47112615-E2E913D0-325B-4C2E-8C3D-6138F6D2BD57Q47131115-6F46A1EE-B13D-40DF-B97E-98978C1CA74EQ50147105-80859CD9-B7A8-47D1-B095-63CB9BC13D6EQ52760604-675CF926-140B-4F5F-ABB2-63BA2AB50262Q53114629-8CF8EE99-24A3-4432-988A-C7CAD691B732Q53481089-FA5171F4-41AE-424C-84A5-418B3BE5ADF7Q56967593-DCF2D565-D1B9-41EA-BE9B-8E187C763A44
P2860
Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Circulating markers of prognos ...... with midgut carcinoid tumours.
@ast
Circulating markers of prognos ...... with midgut carcinoid tumours.
@en
type
label
Circulating markers of prognos ...... with midgut carcinoid tumours.
@ast
Circulating markers of prognos ...... with midgut carcinoid tumours.
@en
prefLabel
Circulating markers of prognos ...... with midgut carcinoid tumours.
@ast
Circulating markers of prognos ...... with midgut carcinoid tumours.
@en
P2093
P2860
P356
P1433
P1476
Circulating markers of prognos ...... with midgut carcinoid tumours.
@en
P2093
Johnston BT
McCance DR
Patterson CC
P2860
P304
P356
10.1136/GUT.2006.092320
P407
P577
2006-03-23T00:00:00Z